40results about How to "Good stability in vitro" patented technology

The invention provides PEGylated benzyltriazolyl pyridazinone compounds of which the molecular formula is Fmppn. The structure of the pyridazinone compounds is disclosed as Formula (1), wherein n is a whole number ranging from 1 to 8; and F is 19F or 18F. The compounds provided by the invention have the characteristics of simple preparation process, low use cost, high radiochemical yield, high radiochemical purity, high stability, favorable biological properties, high target to non-target ratio, high myocardial uptake ratio and the like, and can be applied to the technical fields of radiopharmaceutical chemistry and clinical nuclear medicine as a novel fluorine-18 labeled myocardial perfusion developer.

The invention discloses a PEG (polyethylene glycol) modified recombinant arginine deiminase (ADI) as well as a preparation method and application thereof, belonging to the technical field of biomedical engineering. The stability of ADI-PEG obtained by modifying ADI with PEG in vitro and in mouse plasma is remarkably improved. A pharmacokinetics / pharmacodynamics study shows that compared with free ADI before modification, the half-life period of ADI-PEG in a mouse is prolonged by more than 11 times; the concentration of arginine in the plasma can be reduced and maintained for more than 5 days in the limiting level through single injection of 5U ADI-PEG and can be maintained for 1 day only through injection of unmodified ADI; an H22 liver cancer model mouse is treated for 15 days, and the cancer cell inhibition rate of ADI-PEG (15U) is 95.02% close to 98.34% (the inhibition rate) of a positive control group treated with 5-fluorouracil. PEG modified recombinant arginine deiminase is relatively long in in-vivo half-life period and relatively low in immunogenicity, and serves as an excellent tumor treating or inhibiting drug.

The invention discloses a 99mTc (HYNICNM) (tricine / TPPTS) complex and a preparation method and application thereof. The 99mTc (HYNICNM) (tricine / TPPTS) complex is obtained through two steps of synthesis of a ligand HYNICNM and preparation of a 99mTc (HYNICNM) (tricine / TPPTS) complex. The complex is simple and convenient to prepare and has oxygen deficiency selectivity. Tumor-bearing mice have highuptake and good retention in tumor parts, the tumor / non-target ratio is high, the uptake of non-target organs such as the liver and intestines is obviously reduced, and the 99mTc (HYNICNM) (tricine / TPPTS) complex is a novel tumor hypoxia imaging agent with excellent performance.

The invention relates to euphausia superb symbiotic bacteria, an euphausia superb antioxidant peptide, and a preparation method and application of the euphausia superb antioxidant peptide, belonging to the technical field of microorganisms and biological active peptides. Euphausia superb symbiotic bacteria psychrobacter NL-6 is preserved in China Typical Culture Preservation Center in Wuhan on June 22, 2016, and the preservation number is CCTCCM 2016341. Euphausia superb homogenate is fermented by using the strain to obtain the euphausia superb antioxidant peptide, a hydroxyl radical removal rate of active peptide components, i.e., 1kDa to 5kDa components with highest antioxidant performance reaches 93 percent, the reducing power is 1.32, and an ABTS removal rate is 92.4 percent. The polypeptide is relatively good in stability in vivo and in vitro, better adapts to the requirements of mass production, and relatively good in development and application value as an antioxidant food additive.

The invention belongs to the technical field of biology and provides a 125I-labeled Caerin polypeptide and an application thereof to preparation of a drug for treating tumors and particularly benign and malignant tumors relevant to HPV infection. The 125I-labeled Caerin polypeptide provided by the invention is prepared by using an optimized direct labeling method, and the preparation method is simple and convenient to operate, high in labeling rate, short in reaction time and good in in-vivo and in-vitro stability. The 125I-labeled polypeptide prepared after a Caerin polypeptide is 125I-labeled has a remarkable effect on inhibiting tumor cells and is capable of remarkably improving the treatment effect of the Caerin polypeptide, reducing the use dosage of the Caerin polypeptide and reducing the preparation cost and chemical toxicity of the drug for treating the tumors and particularly tumors relevant to HPV infection, so that the treatment cost of the tumors is reduced, and the medication safety of the tumors is improved.

The invention discloses an application of a mutant single-chain human blood coagulation factor VIII in preparation of a fusion protein of the human blood coagulation factor VIII; the fusion protein sequentially comprises a B-structural domain partially deleted mutant single-chain human coagulation factor VIII, a flexible peptide joint, at least one human chorionic gonadotropin beta subunit carboxyl terminal peptide rigid unit and a half-life prolonging part from an N terminal to a C terminal, and is used for preventing or treating hemorrhagic diseases.

The invention belongs to the technical field of medicinal chemistry and nuclear pharmacy, and discloses an <18>F-labeled EGFR positron imaging agent as well as a preparation method and application thereof. The <18>F-labeled EGFR positron imaging agent has a structure as shown in a formula (II) which is described in the specification. The tracing effect is good, the specificity is relatively good, and high-expression or variant tumors of an epidermal factor receptor (EGFR) can be positively recognized. Meanwhile, the compound is good in in-vitro stability, is mainly metabolized through intestines, galls and kidneys, is quick to remove in vivo, is low in background uptake of background visceral organs and tissues such as muscles, bones, hearts, lungs and livers, and can be used for tumor PET imaging agents, EGFR expression level detection agents and EGFR inhibitor screening agents.

The invention relates to application of a liposome to preparation of a drug for treating chronic viral hepatitis B, wherein the liposome is prepared from a substance containing phospholipid and cholesterol. The invention further relates to application of the liposome to preparation of drugs for promoting serology conversion, namely hepatitis B E antibody positive conversion and hepatitis B E antigen negative conversion, of chronic viral hepatitis B patients, for reducing the titer of hepatitis B virus in peripheral blood serum of chronic viral hepatitis B patients, for reducing the concentration of glutamic-pyruvic transaminase in peripheral blood serum of chronic viral hepatitis B patients, and for maintaining the stability of a T cell receptor repertoire of chronic viral hepatitis B patients.

The invention provides an oxygen-carrying bionic nano antidote, and a preparation method and application thereof. The oxygen-carrying bionic nano antidote with an oxygen-carrying function is obtained by wrapping an oxygen-carrying liquid perfluorocarbon compound with an erythrocyte membrane modified by phospholipid derivative oleic acid oxyethyl phosphorylcholine. The obtained bionic nano antidote is good in detoxification effect, toxin-induced hemolysis can be weakened, the hypoxia phenomenon caused by snake bites is relieved, degenerative necrosis of tissue cells is reduced, and wound healing is promoted.

The invention provides a technetium 99m-marked anti-aspergillus monoclonal antibody for detection of aspergillus, and preparation and application thereof. The technetium 99-marked anti-aspergillus monoclonal antibody is characterized by being prepared through coupling of a difunctional coupling agent NHS-MAG3 with a mouse anti-aspergillus monoclonal antibody Mab-WF-AF-1 and <99m>TcO4<->. The prepared technetium 99m-marked anti-aspergillus monoclonal antibody can be used for qualitative and / or quantitative determination of aspergillus spores in the lung.

The invention discloses a nanoscale ultrasonic contrast agent entrapping perfluorocarbon. The prepared nanoscale ultrasonic contrast agent entrapping the low-boiling point perfluorocarbon inside rapidly vaporizes under the action of body temperature and the ultrasonic effect to produce microbubbles; after receiving ultrasonic energy, the microbubbles resonate and scatter ultrasonic signals to achieve the effect of ultrasonic contrast. The ultrasonic contrast agent has a particle size within a nanoscale range, has high penetrating ability, and has better ability of enhancing imaging; moreover,the nanoscale ultrasonic contrast agent is wrapped by multiple layers of phospholipids, so that storage stability is high, in-vivo ultrasonic stability is high, and biological safety is high; a preparation method is simple; the diagnosis and treatment efficiency can be effectively improved; and the nanoscale ultrasonic contrast agent has very high research value and broad application prospects.

A 99mTc-labeled isonitrile-containing glucose derivative having the general formula [99mTc-(CNDG)6]+, preparation method and use thereof is disclosed herein. The derivative is centered on 99mTc+, and the carbon atom of the isonitrile in CNDG coordinates with 99mTc(I) to form a hexacoordinated complex [99mTc-(CNDG)6]+. The [99mTc-(CNDG)6]+ derivative was obtained by the synthesis of the ligand CNDG and the preparation of the lyophilized CNDG kit. The derivative of the present invention this disclosure has good stability, simple preparation, high uptake and good retention at a tumor site, and high tumor / non-target ratio, and it is a novel 99mTc-labeled isonitrile-containing glucose derivative with excellent performance for tumor imaging. The derivative of the present invention this disclosure is advantageous for popularization and application.

This application relates to the field of biomedical technology, in particular to miRNA markers related to active tuberculosis and their applications, wherein the miRNA markers related to active tuberculosis include miR-451a, miR-25-3p, miR-425 ‑5p, miR‑1260b, miR‑1273g‑3p, miR‑30e‑5p, miR‑140‑3p, let‑7a‑5p, miR‑1290, miR‑491‑5p, miR‑3615, miR‑15a‑5p One or more of miR-21-3p, miR-424-5p, miR-1268a, miR-1301-3p, miR-345-5p, miR-572, miR-375, miR-151a-5p.

The invention discloses a technetium-labeled estradiol derivative and a reference compound thereof, and a preparation method, an application and an intermediate thereof. The technetium-labeled estradiol derivative is shown in the formula VII, wherein A is a group -(CH2CH2)x- or -(CH2CH2O)m(CH2CH2)n-; and x, m and n are integral numbers, x is 1-6, m is 1-3, and n is 1-3. The technetium-labeled estradiol derivative has a moderate lipid / water partition coefficient, and can be used for preparing imaging drugs for diagnosing breast cancer. The in-vitro experiment indicates that the technetium-labeled estradiol derivative has favorable affinity with an estrogen receptor, and has favorable in-vitro stability and moderate metabolism speed in phosphate buffer solution (PBS), 1mM histidine solution, 1mM cysteine solution, 1mM diethylene triamine pentacetic acid (DTPA) solution and newborn calf serum. The technetium-labeled estradiol derivative is hopeful to become a radioactive drug which has good targeting property, is suitable for continuing deep research in organisms and is used for diagnostic imaging.

The invention provides a liposome modified by lactoferrin, which comprises the following raw materials: lactoferrin, egg yolk lecithin, cholesterol, distearoylphosphatidylethanolamine-polyethylene glycol 2000, distearate Acylphosphatidylethanolamine-N-hydroxysuccinimide-polyethylene glycol 2000 and patchouli alcohol; of which, egg yolk lecithin, cholesterol, distearoylphosphatidylethanolamine-polyethylene glycol 2000, distearyl The ratio of acylphosphatidylethanolamine-N-hydroxysuccinimide-polyethylene glycol 2000 is (29~32):(5~7):(5~7):(0.5~1.5)(w / w) ; Wherein, the patchouli alcohol is encapsulated in liposomes; Wherein, the amino group contained in the lactoferrin is passed with distearoylphosphatidylethanolamine-N-hydroxysuccinimide-polyethylene glycol 2000 N-hydroxysuccinimide in the reaction, thus attached to the liposome surface.

Therapeutic compounds useful for the treatment of pathogens including bacteria (gram positive and gram negative, mycobacteria), some fungi and viruses. The compounds described herein may include a mixture of therapeutically-effective amounts of a polar amino acid, a CI 1 fatty acid, and an anthraquinone. The invention further provides for the administration of the therapeutic compounds to a patient (e.g., a human) suffering from an infection.

The invention provides an oxygen-carrying biomimetic nano antidote and its preparation method and application. The red blood cell membrane modified by the phospholipid derivative oleic acid oxyethylphosphorylcholine is used to wrap the oxygen-carrying liquid perfluorocarbon compound to obtain the oxygen-carrying liquid perfluorocarbon compound. Functional biomimetic nano antidote. The obtained biomimetic nano antidote has good detoxification effect, can weaken the hemolysis induced by the toxin, alleviate the hypoxia phenomenon caused by the snake bite, reduce the degeneration and necrosis of tissue cells and promote wound healing.

The invention belongs to the technical field of biology and provides a 125I-labeled Caerin polypeptide and an application thereof to preparation of a drug for treating tumors and particularly benign and malignant tumors relevant to HPV infection. The 125I-labeled Caerin polypeptide provided by the invention is prepared by using an optimized direct labeling method, and the preparation method is simple and convenient to operate, high in labeling rate, short in reaction time and good in in-vivo and in-vitro stability. The 125I-labeled polypeptide prepared after a Caerin polypeptide is 125I-labeled has a remarkable effect on inhibiting tumor cells and is capable of remarkably improving the treatment effect of the Caerin polypeptide, reducing the use dosage of the Caerin polypeptide and reducing the preparation cost and chemical toxicity of the drug for treating the tumors and particularly tumors relevant to HPV infection, so that the treatment cost of the tumors is reduced, and the medication safety of the tumors is improved.